<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>According to the recent data, the determination of the higher titer of antibodies to beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>-I (beta2-GP-I) that is included in a complex compound with negative <z:chebi fb="0" ids="16247">phospholipid</z:chebi> membranes determinates the thrombogenicity in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>To specify this regularity, the authors examined 86 patients with primary APS and 20 patients with venous and <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> without APS </plain></SENT>
<SENT sid="2" pm="."><plain>With increased beta2-GP-I antibody levels, the incidence of thrombotic events was established to w significantly higher than in APS without the increased titer of beta2-GP-I antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>In primary APS-associated persistent <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriage</z:e>, the increased titer of beta2-GP-I is much more infrequently encountered </plain></SENT>
</text></document>